Psilocybin-Assisted Therapy Beats the Nicotine Patch for Smoking Cessation in Pilot Study

groundbreaking pilot study published in JAMA Network Open has found that psilocybin-assisted therapy significantly outperformed the standard nicotine patch when it came to helping smokers quit for good — and the results weren’t even close.

The trial enrolled 82 mentally healthy adult smokers, averaging 47 years of age, all of whom had tried and failed to quit before. Participants were split into two groups: one received a single high dose of psilocybin (30 mg/70 kg) on their target quit date, while the other used an 8-to-10-week FDA-approved nicotine patch regimen. Importantly, both groups went through the same 13-week cognitive behavioral therapy (CBT) program for smoking cessation.

The Results Were Striking

At the six-month mark, 40.5% of participants in the psilocybin group had achieved verified, prolonged abstinence from smoking. In the nicotine patch group, that number was just 10%. The odds of quitting successfully were more than six times higher in the psilocybin group — a statistically significant finding.

Even when looking at a shorter measure — whether someone had been smoke-free for the past seven days at the six-month check-in — the psilocybin group still came out on top: 52.4% vs. 25% for the nicotine patch group.

How Does It Work?

Unlike nicotine patches or other quit-smoking medications that target cravings and withdrawal symptoms directly, psilocybin works in a completely different way. It doesn’t touch the nicotine receptors in the brain at all. Instead, researchers believe it triggers profound psychological shifts — changing how people think about themselves and their habits at a deeper level.

Lead researcher Dr. Matthew Johnson, Associate Professor of Psychiatry at Johns Hopkins University, explained it this way: “The drug causes brain changes that result in a subjective experience that often leads to psychotherapeutic processes, shifts in perspective-taking, and insights.” In other words, it can help people literally change the way they see themselves — including how they identify as a smoker.

Is It Safe?

No serious side effects were linked to either treatment. On the day of dosing, some psilocybin participants experienced temporary increases in blood pressure and heart rate, along with mild headaches, nausea, or visual disturbances — all of which resolved on their own. Because psilocybin was given as a single dose rather than an ongoing prescription, the long-term side effects seen with many smoking cessation drugs were simply not a factor.

Why This Matters

Smoking remains one of the leading causes of preventable death, linked to lung cancer, COPD, heart disease, and more. While existing approved medications help, long-term quit rates in real-world settings remain disappointingly low. This study opens a new door.

Dr. Frank Leone, Director of the University of Pennsylvania’s Comprehensive Smoking Treatment Program, called the findings a meaningful step forward: “It expands our point of view on what constitutes appropriate types of interventions for addictive behaviors and how new learned pathways in the brain are formed and reformed over time.”

What’s Next?

The researchers are the first to acknowledge the study’s limitations — it was unblinded, the sample skewed toward White, highly educated participants, and the psilocybin group had more supervised contact time overall. A larger, blinded Phase 2 clinical trial is already underway.

Dr. Leone noted that real-world questions still need answers: “Who and how will it be administered and monitored? What are the long-term complications? What do you do if it doesn’t work the first time?” Those are the kinds of questions larger trials will need to tackle.

But for now, the signal is clear: psilocybin-assisted therapy is a serious contender in the fight against tobacco addiction — and science is just getting started.

Source: Johnson MW et al. Psilocybin or nicotine patch for smoking cessation: a pilot randomized clinical trial. JAMA Netw Open. 2026;9(3):e260972. Original article: chestphysician.org